Vir Biotechnology Inc. (VIR) Tops Q4 EPS by 23c

Vir Biotechnology Inc. (NASDAQ: VIR) reported Q4 EPS of ($0.31), $0.23 better than the analyst estimate of ($0.54). Revenue for the quarter came in at $64.07 million versus the consensus estimate of $1.42 million.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.

You May Also Be Interested In

• Citi upgrades Bath & Body Works to Buy with $25 price target
• Dynatrace Inc. (DT) PT Raised to $65 at Citi, Adds Catalyst Watch
• XP Inc. (XP) Tops Q2 EPS by 8c